Limits...
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Wen FT, Thisted RA, Rowley DA, Schreiber H - Oncoimmunology (2012)

Bottom Line: The predominant effect of cancer immunotherapies was slowed or delayed outgrowth.Together, these results indicate that most recent studies, using many diverse approaches, still treat small tumors only to report slowed or delayed growth.Nevertheless, a few recent studies indicate effective therapy against large tumors when using passive antibody or adoptive T cell therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology; The University of Chicago; Chicago, IL USA.

ABSTRACT
We conducted a systematic analysis to determine the reason for the apparent disparity of success of immunotherapy between clinical and experimental cancers. To do this, we performed a search of PubMed using the keywords "immunotherapy" AND "cancer" for the years of 1980 and 2010. The midspread of experimental tumors used in all the relevant literature published in 2010 were between 0.5-121 mm(3) in volume or had grown for four to eight days. Few studies reported large tumors that could be considered representative of clinical tumors, in terms of size and duration of growth. The predominant effect of cancer immunotherapies was slowed or delayed outgrowth. Regression of tumors larger than 200 mm(3) was observed only after passive antibody or adoptive T cell therapy. The effectiveness of other types of immunotherapy was generally scattered. By comparison, very few publications retrieved by the 1980 search could meet our selection criteria; all of these used tumors smaller than 100 mm(3), and none reported regression. In the entire year of 2010, only 13 used tumors larger than 400 mm(3), and nine of these reported tumor regression. Together, these results indicate that most recent studies, using many diverse approaches, still treat small tumors only to report slowed or delayed growth. Nevertheless, a few recent studies indicate effective therapy against large tumors when using passive antibody or adoptive T cell therapy. For the future, we aspire to witness the increased use of experimental studies treating tumors that model clinical cancers in terms of size and duration of growth.

No MeSH data available.


Related in: MedlinePlus

Figure 2. Most experimental tumors are treated less than a week after tumor cell inoculation. The median time reported was five days. All 158 cancer immunotherapy studies listed in PubMed meeting our selection criteria for 2010 using syngeneic murine tumor models are presented. Only nine tumors have grown for 14 d or longer before treatment. (n = 158; Q1 = 4, Q2 = 5, Q3 = 8)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3377001&req=5

Figure 2: Figure 2. Most experimental tumors are treated less than a week after tumor cell inoculation. The median time reported was five days. All 158 cancer immunotherapy studies listed in PubMed meeting our selection criteria for 2010 using syngeneic murine tumor models are presented. Only nine tumors have grown for 14 d or longer before treatment. (n = 158; Q1 = 4, Q2 = 5, Q3 = 8)

Mentions: From the 195 publications reporting size data in 2010, we extracted the time given for tumors to establish before treatment was given. Xenotransplanted tumors were excluded only from this particular analysis due to the irregular growth kinetics of xenografts in immunocompromised hosts. After excluding xenotransplants, 158 publications reported the time when treatment was given after tumor cell inoculation. The distribution of times given for tumors to grow before treatment is presented Figure 2. The median time was 5 d. The bulk of publications cluster around tumors that have grown for 4–8 d before treatment. Only 15 publications reported tumors that had grown for 14 d or longer before treatment.


A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Wen FT, Thisted RA, Rowley DA, Schreiber H - Oncoimmunology (2012)

Figure 2. Most experimental tumors are treated less than a week after tumor cell inoculation. The median time reported was five days. All 158 cancer immunotherapy studies listed in PubMed meeting our selection criteria for 2010 using syngeneic murine tumor models are presented. Only nine tumors have grown for 14 d or longer before treatment. (n = 158; Q1 = 4, Q2 = 5, Q3 = 8)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3377001&req=5

Figure 2: Figure 2. Most experimental tumors are treated less than a week after tumor cell inoculation. The median time reported was five days. All 158 cancer immunotherapy studies listed in PubMed meeting our selection criteria for 2010 using syngeneic murine tumor models are presented. Only nine tumors have grown for 14 d or longer before treatment. (n = 158; Q1 = 4, Q2 = 5, Q3 = 8)
Mentions: From the 195 publications reporting size data in 2010, we extracted the time given for tumors to establish before treatment was given. Xenotransplanted tumors were excluded only from this particular analysis due to the irregular growth kinetics of xenografts in immunocompromised hosts. After excluding xenotransplants, 158 publications reported the time when treatment was given after tumor cell inoculation. The distribution of times given for tumors to grow before treatment is presented Figure 2. The median time was 5 d. The bulk of publications cluster around tumors that have grown for 4–8 d before treatment. Only 15 publications reported tumors that had grown for 14 d or longer before treatment.

Bottom Line: The predominant effect of cancer immunotherapies was slowed or delayed outgrowth.Together, these results indicate that most recent studies, using many diverse approaches, still treat small tumors only to report slowed or delayed growth.Nevertheless, a few recent studies indicate effective therapy against large tumors when using passive antibody or adoptive T cell therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology; The University of Chicago; Chicago, IL USA.

ABSTRACT
We conducted a systematic analysis to determine the reason for the apparent disparity of success of immunotherapy between clinical and experimental cancers. To do this, we performed a search of PubMed using the keywords "immunotherapy" AND "cancer" for the years of 1980 and 2010. The midspread of experimental tumors used in all the relevant literature published in 2010 were between 0.5-121 mm(3) in volume or had grown for four to eight days. Few studies reported large tumors that could be considered representative of clinical tumors, in terms of size and duration of growth. The predominant effect of cancer immunotherapies was slowed or delayed outgrowth. Regression of tumors larger than 200 mm(3) was observed only after passive antibody or adoptive T cell therapy. The effectiveness of other types of immunotherapy was generally scattered. By comparison, very few publications retrieved by the 1980 search could meet our selection criteria; all of these used tumors smaller than 100 mm(3), and none reported regression. In the entire year of 2010, only 13 used tumors larger than 400 mm(3), and nine of these reported tumor regression. Together, these results indicate that most recent studies, using many diverse approaches, still treat small tumors only to report slowed or delayed growth. Nevertheless, a few recent studies indicate effective therapy against large tumors when using passive antibody or adoptive T cell therapy. For the future, we aspire to witness the increased use of experimental studies treating tumors that model clinical cancers in terms of size and duration of growth.

No MeSH data available.


Related in: MedlinePlus